In September 2025, Kashiv BioSciences launched Pexegra (pegfilgrastim), a biosimilar referencing Amgen’s Neulasta, and Filra (filgrastim), a biosimilar referencing Amgen’s Neupogen, in the Canadian market. Additionally, Tanvex Biopharma announced its biosimilar drug Nypozi (filgrastim) is now available in the US market through marketing partner Cipla.
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue filgrastim. It stimulates the production of white blood cells (neutrophils). Pegfilgrastim treatment is used to encourage bone marrow to produce more neutrophils to help fight infection in patients undergoing chemotherapy [1].
The launch of Pexegra in Canada comes after the product was granted marketing authorization in February 2025 [2]. Pexegra is a long-acting G-CSF biosimilar indicated for reducing incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies undergoing myelosuppressive antineoplastic therapy.
Filgrastim is a granulocyte colony-stimulating factor (G-CSF). Filgrastim treatment can be used to stimulate the bone marrow to produce more neutrophils (white blood cells) to fight infection in patients undergoing chemotherapy for cancer treatment [3].
Kashiv BioSciences have now launched Filra in Canada and Pexegra and Filra biosimilars will be marketed through an exclusive agreement with JAMP Pharma Corporation.
After the product was approved in June 2024 [4], Tanvex Biopharma is now the first Taiwanese company to launch a biosimilar product to the US market. Under its contract with Cipla, Tanvex will be responsible for mass production and supply and will share in revenue and royalties with the marketing partner. This product has also been approved in Canada [5].
Related article
Clinical trial advances for Kashiv and Celltrion
|
LATIN AMERICAN FORUM
The objective of GaBI’s Latin American Forum is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View the latest headline article: La EMA recomienda la aprobación de nueve biosimilares Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.
FORO LATINOAMERICANO
El objetivo del Foro Latinoamericano de GaBI es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Ver el último artículo de cabecera: La EMA recomienda la aprobación de nueve biosimilares !Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.
|
References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of pegfilgrastim [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2025 Nov 21]. Available from: www.gabionline.net/biosimilars/general/Biosimilars-of-pegfilgrastim
2. GaBI Online - Generics and Biosimilars Initiative. Canada approves pegfilgrastim biosimilar Pexegra [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2025 Nov 21]. Available from: www.gabionline.net/biosimilars/news/canada-approves-pegfilgrastim-biosimilar-pexegra
3. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of filgrastim [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2025 Nov 20]. Available from: www.gabionline.net/biosimilars/general/Biosimilars-of-filgrastim
4. GaBI Online - Generics and Biosimilars Initiative. FDA approves filgrastim biosimilar Nypozi [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2025 Nov 20]. Available from: www.gabionline.net/biosimilars/news/fda-approves-filgrastim-biosimilar-nypozi
5. GaBI Online - Generics and Biosimilars Initiative. Canada approves filgrastim biosimilar Nypozi [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2025 Nov 20]. Available from: www.gabionline.net/biosimilars/news/canada-approves-filgrastim-biosimilar-nypozi
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2025 Pro Pharma Communications International. All Rights Reserved.
0
Post your comment